![\"Radiation](\"https:\/\/rtmedical.com.br\/wp-content\/uploads\/2026\/04\/astro-medicare-rocr-radiation-oncology.jpg\")
What the ROCR Act actually proposes<\/h2>\n
The ROCR Act reframes the logic of Medicare reimbursement in radiation oncology: instead of paying per service delivered, payment shifts to a case-rate model based on the individual treatment plan. ASTRO argues that this design brings financial predictability, aligns incentives with clinical quality and protects smaller clinics that today must absorb fluctuations in reimbursement after each tariff update.<\/p>\n
The case-rate model also fits broader episode-of-care payment trends, where the focus moves from volume to clinical outcome over the patient’s full treatment cycle. For radiation oncology, that means a “bundle” covering fractionation, planning, quality control and follow-up \u2014 instead of fragmented billing per code.<\/p>\n
The numbers behind the alarm<\/h2>\n
A recent ASTRO survey found that more than two-thirds of U.S. radiation oncology practices reported double-digit reimbursement declines in early 2026, following updates to radiation treatment delivery codes. Some practices indicated the cuts could jeopardize their financial stability. “If these new cuts are sustained for longer than 1-2 months, we will be at a very real risk of needing to declare bankruptcy,” one physician told ASTRO.<\/p>\n
The long-term picture is equally tight. ASTRO data show that Medicare reimbursement for radiation therapy has dropped 27% since 2013, while operating costs have increased. A separate analysis points to a 13% decline in the number of organizations employing radiation oncologists over the past decade \u2014 a clear sign of consolidation, with smaller clinics closing or being absorbed into larger hospital networks.<\/p>\n
Prior authorization as an additional barrier<\/h2>\n
Beyond tariff pressure, ASTRO highlights prior authorization under Medicare Advantage as an additional barrier. Survey data point to delays in treatment approvals and increased administrative workload, with some clinicians reporting longer processing times and adverse patient outcomes tied to authorization delays. For the patient, that translates into days or weeks of additional waiting between diagnosis and the actual start of radiation therapy \u2014 a window that can be critical for local disease control.<\/p>\n
ASTRO is also asking Congress to support the Improving Seniors’ Timely Access to Care Act, which would set timelines for authorization decisions and require greater transparency from insurers. According to the society, the combination of ROCR plus prior-authorization reform is the minimum package to prevent further erosion of access to community-based oncologic care.<\/p>\n
Why this resonates beyond the United States<\/h2>\n
While the ROCR Act is strictly a U.S. congressional agenda, the underlying scenario has clear parallels for other systems. Private radiation therapy clinics in many countries also face billing rejections, payer payment delays and rising costs to maintain linear accelerators and treatment planning software. Recent discussions about hospital expansions in oncology and radiation therapy<\/a> and the decline of radiation therapist vacancies in the U.S.<\/a> form the same picture: the field advances technologically while still wrestling with major structural issues around financing and workforce.<\/p>\n Public health systems also struggle with uneven access to radiation therapy, especially across geographically large countries. Episode-of-care payment models, similar in spirit to ROCR, are being debated in private and supplemental health markets and may gain ground if they prove sustainable in the U.S.<\/p>\n Three practical points emerge for service managers. First, monitoring the cost structure of each case treated, tied back to the clinical plan, becomes increasingly important to assess financial viability under case-rate models. Second, automating administrative tasks \u2014 scheduling, authorizations, quality reports \u2014 frees clinical time and protects operating margin. Third, investing in protocol consistency and quality control reduces rework, planning errors and revenue loss to billing rejections, especially in advanced techniques such as SBRT, IMRT and VMAT.<\/p>\n For the practicing radiation oncologist, the discussion is equally tangible. Adopting moderate or ultra-hypofractionation protocols when clinically appropriate cuts session volume while maintaining or improving quality \u2014 a topic that ties into debates about AI applied to radiation therapy planning<\/a>. Properly documenting the clinical rationale of each decision also protects the patient in prior-authorization scenarios and strengthens the clinic’s position in audits.<\/p>\n ASTRO also called for greater federal investment in cancer research, advocating for funding levels for the NIH, the National Cancer Institute and ARPA-H. “The data in our new survey signal a serious threat to cancer care access,” said Sameer Keole, M.D., FASTRO, ASTRO board chair. “Congress has the tools to fix these problems, and we’re asking them to act now before people with cancer lose access to the care that can save their lives.”<\/p>\n Politically, the window for these laws depends on Congress’s calendar and on the fiscal priorities of each administration. The risk for the field is that legislative time runs slower than the pace of tariff cuts, opening room for clinic closures in rural and underserved communities \u2014 precisely those already facing more barriers to oncologic care.<\/p>\n The ROCR case is a reminder that reimbursement decisions directly shape access to oncologic care. Volume-based payment models tend to concentrate services in large centers; episode-based models can sustain more distributed networks, provided they are properly adjusted for case-mix complexity. For the radiation oncologist, this is a moment to engage in management and public policy discussions rather than watch from the sidelines.<\/p>\n ASTRO’s message to Congress is clear: now is the time. For health systems abroad, it is worth tracking how this U.S. regulation evolves, because models that work there tend to inform meaningful debates in private and public oncology elsewhere.<\/p>\nImplications for radiation oncology managers and professionals<\/h2>\n
Research, NIH and the political context<\/h2>\n
Outlook: financing as a vector of equity<\/h2>\n